O	0	3	The
O	4	11	Effects
O	12	14	of
B-intervention	15	26	Ganglioside
I-intervention	26	27	-
I-intervention	27	37	Monosialic
I-intervention	38	42	Acid
O	43	45	in
B-condition	46	52	Taxane
I-condition	52	53	-
I-condition	53	60	Induced
I-condition	61	71	Peripheral
I-condition	72	85	Neurotoxicity
O	86	88	in
O	89	97	Patients
O	98	102	with
O	103	109	Breast
O	110	116	Cancer
O	116	117	:
O	118	119	A
O	120	130	Randomized
O	131	136	Trial
O	136	137	.

O	138	144	Taxane
O	144	145	-
O	145	152	induced
O	153	163	peripheral
O	164	174	neuropathy
O	175	176	(
O	176	180	TIPN
O	180	181	)
O	182	184	is
O	185	186	a
O	187	191	dose
O	191	192	-
O	192	200	limiting
O	201	208	adverse
O	209	215	effect
O	215	216	.

O	217	228	Ganglioside
O	228	229	-
O	229	239	monosialic
O	240	244	acid
O	245	246	(
O	246	249	GM1
O	249	250	)
O	251	260	functions
O	261	263	as
O	264	265	a
O	266	281	neuroprotective
O	282	288	factor
O	288	289	.

O	290	292	We
O	293	301	assessed
O	302	305	the
O	306	313	effects
O	314	316	of
O	317	320	GM1
O	321	323	on
O	324	327	the
O	328	338	prevention
O	339	341	of
O	342	346	TIPN
O	347	349	in
O	350	356	breast
O	357	363	cancer
O	364	372	patients
O	372	373	.

O	374	376	We
O	377	386	conducted
O	387	388	a
O	389	399	randomized
O	399	400	,
O	401	407	double
O	407	408	-
O	408	413	blind
O	413	414	,
O	415	422	placebo
O	422	423	-
O	423	433	controlled
O	434	439	trial
O	440	449	including
B-total-participants	450	453	206
B-eligibility	454	462	patients
I-eligibility	463	467	with
I-eligibility	468	473	early
I-eligibility	473	474	-
I-eligibility	474	479	stage
I-eligibility	480	486	breast
I-eligibility	487	493	cancer
I-eligibility	494	502	planning
I-eligibility	503	505	to
I-eligibility	506	513	receive
I-eligibility	514	520	taxane
I-eligibility	520	521	-
I-eligibility	521	526	based
I-eligibility	527	535	adjuvant
I-eligibility	536	548	chemotherapy
I-eligibility	549	553	with
I-eligibility	554	555	a
I-eligibility	556	562	follow
I-eligibility	562	563	-
I-eligibility	563	565	up
I-eligibility	566	568	of
I-eligibility	569	573	more
I-eligibility	574	578	than
I-eligibility	579	580	1
I-eligibility	581	585	year
O	585	586	.

O	587	595	Subjects
O	596	600	were
O	601	609	randomly
O	610	618	assigned
O	619	621	to
O	622	629	receive
O	630	633	GM1
O	634	635	(
O	635	637	80
O	638	640	mg
O	640	641	,
O	642	645	day
O	646	647	-
O	647	648	1
O	649	651	to
O	652	655	day
O	656	657	2
O	657	658	)
O	659	661	or
B-control	662	669	placebo
O	669	670	.

O	671	674	The
O	675	682	primary
O	683	691	endpoint
O	692	695	was
O	696	699	the
B-outcome-Measure	700	710	Functional
I-outcome-Measure	711	721	Assessment
I-outcome-Measure	722	724	of
I-outcome-Measure	725	731	Cancer
I-outcome-Measure	732	741	Treatment
I-outcome-Measure	742	755	Neurotoxicity
I-outcome-Measure	756	764	subscale
I-outcome-Measure	765	770	score
I-outcome-Measure	771	776	after
I-outcome-Measure	777	781	four
I-outcome-Measure	782	788	cycles
I-outcome-Measure	789	791	of
I-outcome-Measure	792	804	chemotherapy
O	804	805	.

O	806	815	Secondary
O	816	825	endpoints
O	826	834	included
B-outcome-Measure	835	848	neurotoxicity
I-outcome-Measure	849	858	evaluated
I-outcome-Measure	859	861	by
I-outcome-Measure	862	870	National
I-outcome-Measure	871	877	Cancer
I-outcome-Measure	878	887	Institute
I-outcome-Measure	888	894	Common
I-outcome-Measure	895	906	Terminology
I-outcome-Measure	907	915	Criteria
I-outcome-Measure	916	919	for
I-outcome-Measure	920	927	Adverse
I-outcome-Measure	928	934	Events
I-outcome-Measure	935	942	Version
I-outcome-Measure	943	944	4
I-outcome-Measure	944	945	.
I-outcome-Measure	945	946	0
I-outcome-Measure	947	950	and
I-outcome-Measure	951	954	the
I-outcome-Measure	955	962	Eastern
I-outcome-Measure	963	974	Cooperative
I-outcome-Measure	975	983	Oncology
I-outcome-Measure	984	989	Group
I-outcome-Measure	990	1000	neuropathy
I-outcome-Measure	1001	1006	scale
O	1006	1007	.

O	1008	1011	All
O	1012	1023	statistical
O	1024	1029	tests
O	1030	1034	were
O	1035	1038	two
O	1038	1039	-
O	1039	1044	sided
O	1044	1045	.

O	1046	1048	In
B-total-participants	1049	1052	183
O	1053	1062	evaluable
O	1063	1071	patients
O	1071	1072	,
O	1073	1076	the
O	1077	1080	GM1
O	1081	1086	group
O	1087	1095	reported
O	1096	1102	better
B-outcome	1103	1107	mean
I-outcome	1108	1118	Functional
I-outcome	1119	1129	Assessment
I-outcome	1130	1132	of
I-outcome	1133	1139	Cancer
I-outcome	1140	1149	Treatment
I-outcome	1150	1163	Neurotoxicity
I-outcome	1164	1172	subscale
I-outcome	1173	1179	scores
O	1180	1184	than
O	1185	1193	patients
O	1194	1196	in
O	1197	1200	the
O	1201	1208	placebo
O	1209	1214	group
O	1215	1220	after
O	1221	1225	four
O	1226	1232	cycles
O	1233	1235	of
O	1236	1248	chemotherapy
O	1249	1250	(
B-iv-cont-mean	1250	1252	43
I-iv-cont-mean	1252	1253	.
I-iv-cont-mean	1253	1255	27
O	1255	1256	,
O	1257	1259	95
O	1259	1260	%
O	1261	1271	confidence
O	1272	1280	interval
O	1281	1282	[
O	1282	1284	CI
O	1284	1285	]
O	1286	1287	=
O	1288	1290	43
O	1290	1291	.
O	1291	1293	05
O	1294	1296	to
O	1297	1299	43
O	1299	1300	.
O	1300	1302	49
O	1303	1305	vs
B-cv-cont-mean	1306	1308	34
I-cv-cont-mean	1308	1309	.
I-cv-cont-mean	1309	1311	34
O	1311	1312	,
O	1313	1315	95
O	1315	1316	%
O	1317	1319	CI
O	1320	1321	=
O	1322	1324	33
O	1324	1325	.
O	1325	1327	78
O	1328	1330	to
O	1331	1333	34
O	1333	1334	.
O	1334	1336	89
O	1336	1337	;
O	1338	1342	mean
O	1343	1353	difference
O	1354	1355	=
O	1356	1357	8
O	1357	1358	.
O	1358	1360	96
O	1360	1361	,
O	1362	1364	95
O	1364	1365	%
O	1366	1368	CI
O	1369	1370	=
O	1371	1372	8
O	1372	1373	.
O	1373	1375	38
O	1376	1378	to
O	1379	1380	9
O	1380	1381	.
O	1381	1383	54
O	1383	1384	,
O	1385	1386	P
O	1387	1388	<
O	1389	1390	.
O	1390	1393	001
O	1393	1394	)
O	1394	1395	.

B-outcome	1396	1401	Grade
I-outcome	1402	1403	1
I-outcome	1404	1406	or
I-outcome	1407	1413	higher
I-outcome	1414	1424	peripheral
I-outcome	1425	1438	neurotoxicity
O	1439	1441	in
O	1442	1448	Common
O	1449	1460	Terminology
O	1461	1469	Criteria
O	1470	1473	for
O	1474	1481	Adverse
O	1482	1488	Events
O	1489	1491	v4
O	1491	1492	.
O	1492	1493	0
O	1494	1499	scale
O	1500	1503	was
O	1504	1517	statistically
O	1518	1531	significantly
O	1532	1537	lower
O	1538	1540	in
O	1541	1544	the
O	1545	1548	GM1
O	1549	1554	group
O	1555	1556	(
B-iv-bin-percent	1556	1558	14
I-iv-bin-percent	1558	1559	.
I-iv-bin-percent	1559	1560	3
I-iv-bin-percent	1560	1561	%
O	1562	1564	vs
B-cv-bin-percent	1565	1568	100
I-cv-bin-percent	1568	1569	.
I-cv-bin-percent	1569	1570	0
I-cv-bin-percent	1570	1571	%
O	1571	1572	,
O	1573	1574	P
O	1575	1576	<
O	1577	1578	.
O	1578	1581	001
O	1581	1582	)
O	1582	1583	.

O	1584	1596	Additionally
O	1596	1597	,
O	1598	1601	the
O	1602	1605	GM1
O	1606	1611	group
O	1612	1615	had
O	1616	1617	a
O	1618	1631	statistically
O	1632	1645	significantly
O	1646	1651	lower
B-outcome	1652	1661	incidence
I-outcome	1662	1664	of
I-outcome	1665	1670	grade
I-outcome	1671	1672	1
I-outcome	1673	1675	or
I-outcome	1676	1682	higher
I-outcome	1683	1696	neurotoxicity
O	1697	1705	assessed
O	1706	1708	by
O	1709	1716	Eastern
O	1717	1728	Cooperative
O	1729	1737	Oncology
O	1738	1743	Group
O	1744	1754	neuropathy
O	1755	1760	scale
O	1761	1768	sensory
O	1769	1779	neuropathy
O	1780	1781	(
B-iv-bin-percent	1781	1783	26
I-iv-bin-percent	1783	1784	.
I-iv-bin-percent	1784	1785	4
I-iv-bin-percent	1785	1786	%
O	1787	1789	vs
B-cv-bin-percent	1790	1792	97
I-cv-bin-percent	1792	1793	.
I-cv-bin-percent	1793	1794	8
I-cv-bin-percent	1794	1795	%
O	1795	1796	,
O	1797	1798	P
O	1799	1800	<
O	1801	1802	.
O	1802	1805	001
O	1805	1806	)
O	1807	1810	and
B-outcome	1811	1816	motor
I-outcome	1817	1827	neuropathy
I-outcome	1828	1837	subscales
O	1838	1839	(
B-iv-bin-percent	1839	1841	20
I-iv-bin-percent	1841	1842	.
I-iv-bin-percent	1842	1843	9
I-iv-bin-percent	1843	1844	%
O	1845	1847	vs
B-cv-bin-percent	1848	1850	81
I-cv-bin-percent	1850	1851	.
I-cv-bin-percent	1851	1852	5
I-cv-bin-percent	1852	1853	%
O	1853	1854	,
O	1855	1856	P
O	1857	1858	<
O	1859	1860	.
O	1860	1863	001
O	1863	1864	)
O	1864	1865	.

O	1866	1869	The
O	1870	1879	treatment
O	1880	1884	with
O	1885	1888	GM1
O	1889	1897	resulted
O	1898	1900	in
O	1901	1902	a
O	1903	1912	reduction
O	1913	1915	in
O	1916	1919	the
O	1920	1928	severity
O	1929	1932	and
O	1933	1942	incidence
O	1943	1945	of
O	1946	1950	TIPN
O	1951	1956	after
O	1957	1961	four
O	1962	1968	cycles
O	1969	1971	of
O	1972	1978	taxane
O	1978	1979	-
O	1979	1989	containing
O	1990	2002	chemotherapy
O	2003	2005	in
O	2006	2014	patients
O	2015	2019	with
O	2020	2026	breast
O	2027	2033	cancer
O	2033	2034	.
